

Index

(Page numbers in italics indicate figures;
page numbers followed by “t” indicate tables.)

Acetaminophen, 159t
Acetylcholine receptor blockade
 consequences of, 48t
 tricyclic antidepressants and, 67
Age, SSRI clearance rate and, 120t-121t, 124-125
Alcohol, antidepressant interaction with, 65 -66
Alfentanil, 159t
 α -Adrenergic receptor blockade, 49t
Alprazolam
 CYP enzyme metabolism of, 159t
 drug interactions with, 190-192, 193t
Alprenolol, 158t
Amidarone, 159t
Amitriptyline
 CYP enzyme metabolism of, 158t-159t
 dopamine uptake and, 39t
 norepinephrine uptake and, 38t, 41
 polypharmacy of, 25t
 potency of, 27
 selectivity of, 41, 46t
 serotonin uptake and, 37t, 41
 side effects of, 70
Analgesic(s), 159t
Androstendione, 159t
Anesthetic(s), local, 159t
Anorexia
 imipramine and, 68t
 serotonin uptake blockade and, 48t
 SSRIs and, 82t, 86t, 87
Antiarrhythmic drug(s)
 CYP enzyme metabolism of, 158t-159t
 drug interactions with, 184
Antibiotic(s), 159t
Anticonvulsant drug(s), 159t
Antidepressant(s). See also specific drug, eg, *Fluoxetine*;
 specific type of drug, eg, *Monoamine oxidase inhibitor(s)*.
 action mechanisms of, 16t
 CYP enzyme metabolism of, 158t-159t
 pharmacology of, 48t-49t
 prevalence of other drugs with, prevalence of, 162t
 side effects of, 48t-49t
 in vitro profile of, 53

Antiestrogen drug(s), 159t
 Antihistamine(s), 159t
 Antipsychotic drug(s), 158t-159t
 Anxiety
 amitriptyline and, 70
 serotonin uptake blockade and, 48t
 sertraline and, 70
 SSRIs and, 86t
 Astemizole
 CYP enzyme metabolism of, 159t
 drug interactions with, 153t
 Asthenia
 serotonin uptake blockade and, 48t
 SSRIs and, 86t

 Barbiturate(s), 158t
 Benzodiazepine(s)
 CYP enzyme metabolism of, 159t
 development of, 20
 SSRI(s) interaction with, 66
 Benzphetamine, 159t
 Benztropine, 25t
 β -Blocker(s)
 CYP enzyme metabolism of, 158t
 drug interactions with, 184
 Bupropion
 fluoxetine interaction with, 150
 seizure risk with, 149, 150
 Burarolol, 158t

 Caffeine, 158t
 Calcium channel blocker(s), 159t
 Carbamazepine
 CYP enzyme metabolism of, 159t
 drug interactions with, 152t, 156, 192, 193t
 Carcinogenesis, CYP enzyme 2D6 and, 138-140
 Central depressant drug(s), histamine receptor blockade and, 48t
 Chirality, 29-32
 Cimetidine
 action mechanism of, 25t
 drug interactions with, 152t
 Cisapride, 159t
 Citalopram. See also *Desmethylcitalopram*.
 availability of, 18
 brand names of, by country, 234t-236t
 chirality of, 30-31

238

clearance of, age and gender and, 120t, 124-125
 CYP enzymes and, 176t-177t
 2D6 deficiency and, 165t
 2D6 functions and, 179t, 185, 186
 inhibition by, 170t-171t
 metabolism of, 158t
 development of, 16
 dopamine uptake and, 39t
 dosage of
 age and, plasma level and, 120t
 potency and, 50t, 51-52
 half-life of, 60t, 109t, 118t, 119
 cirrhosis and, 127t
 metabolism of, 110-111, 111t
 metabolites of, potency of, 57, 58t
 norepinephrine uptake and, 38t, 41
 pharmacokinetics of, 109t
 linear *versus* nonlinear, 117-119
 selectivity of, 41, 46t
 serotonin uptake and, 37t, 41
 dosage and, 50t, 51-52
 steady-state of, time to, 123
 structural formula of, 17
in vitro profile of, 53
 washout of, 123
 Citalopram enantiomer(s), 44t
 Clarithromycin, 159t
 Clomipramine. See also *Desmethylclomipramine*.
 action mechanisms of, 52, 54
 CYP enzyme metabolism of, 158t, 159t
 demethylation of, 55
 potency and, 56
 dopamine uptake and, 39t
 half-life of, 60t
 for major depression, 54
 norepinephrine uptake and, 38t, 41
 for obsessive-compulsive disorder, 54
 selectivity of, 46t
 side effects and, 54
 selectivity ratio of, 41
 serotonin uptake and, 37t, 41
 sodium channel inhibition by, 54
 in vitro profile of, 53
 Clonazepam, 159t
 Clonidine
 adrenergic blocker interaction with, 49t
 antidepressant interaction with, 49t

239

Clorpheniramine, action mechanism of, 25t
Clozapine
 CYP enzyme metabolism of, 158t, 159t
 seizure risk with, 148, 149
Cocaine, 159t
Codeine
 CYP enzyme metabolism of, 158t, 159t
 drug interactions with, 153t, 184
Constipation
 acetylcholine receptor blockade and, 48t
 amitriptyline and, 70
 imipramine and, 68, 68t
 sertraline and, 70
 SSRIs and, 83t, 86t
Cortisol, 159t
Cyclosporine, 159t
CYP enzyme(s)
 antidepressant demethylation and, 55-56
 citalopram metabolism by, 110-111, 111t
 classification of, 132-133, 134t
 clozapine metabolism by, 150
 deficiency of, 138-140
 genetically determined, 160t
 discovery of, 131t, 131-132, 133t
 drug clearance and, 140-141, 141-142, 143
 drug metabolism by, 135, 136, 137
 drug-drug interactions and, 143-144, 152t-153t
 fluoxetine metabolism by, 111t, 111-113
 fluvoxamine metabolism by, 111t, 111-112
 functions of, 136t, 138
 genetics of, 134t, 137
 inhibition constant and, 227-232
 inhibition of
 consequences of, 163, 164t
 in vitro studies of, 167t, 167-169, 170t-171t
 in vivo studies of, 167t, 172, 173, 174-175
 norfluoxetine inhibition of, 59
 oxidative metabolism and, 137, 139
 paroxetine metabolism by, 111t, 113-114
 reaction cycle of, 138
 risperidone metabolism by, 148
 sertraline metabolism by, 111t, 114-115
 SSRI inhibition of, 78, 98
 steroidogenic, 133, 134t, 135, 136t
 tricyclic antidepressant metabolism by, 151
 xenobiotic, 134t, 135, 136t, 175, 176t-177t, 178
CYP enzyme 1A2

 drugs metabolized by, 158t
 effects of specific SSRIs on, 176t-177t, 178, 180-181
CYP enzyme 2C9/10
 drugs metabolized by, 158t
 effects of specific SSRIs on, 176t-177t, 181-182, 193t
CYP enzyme 2C19, effects of specific SSRIs on, 176t-177t, 182-183, 193t
CYP enzyme 2D6
 carcinogenesis and, 138-140
 deficiency of, drug-induced, 163
 dopamine uptake transporter pump and, 137
 drugs metabolized by, 158t
 effects of specific SSRIs on, 176t-177t, 179t-180t, 184, 185, 186-187, 190, 230t
 myths concerning, 164, 166, 166t
 tricyclic antidepressant toxicity and, 100-101
CYP enzyme 3A3/4
 drugs metabolized by, 159t
 effects of specific SSRIs on, 176t-177t, 190-192, 193t, 194
Cytochrome P450 enzyme(s). See *CYP enzyme(s)*.

Dapsone, 159t
Debrisoquin, 158t
Dehydroepiandrosterone 3-sulfate, 159t
Depression, major
 clomipramine for, 54
 prevalence of medical illnesses with, 162t
 SSRI(s) for, 75t
 tricyclic antidepressants for, 72
Desipramine
 action mechanism of, 25t
 CYP 2D6 functions and, 186, 188-189
 dopamine uptake and, 39t
 drug interactions with, 173, 186, 188-189
 norepinephrine uptake and, 38t, 41
 selectivity of, 41, 46t
 serotonin uptake and, 37t, 41
Desmethylcitalopram
 CYP enzymes and
 inhibition by, 170t-171t
 metabolism of, 158t
 potency of, 58t, 60t
Desmethyloclozapine
 clinical relevance of, 60t
 CYP enzyme metabolism of, 158t
 half-life of, 60t
 potency of, 44t, 58t

selectivity of, 41
in vitro profile of, 53
Desmethylsertraline
 CYP enzymes and, 115
 inhibition by, 170t-171t
 pharmacokinetics of, 116-117
 potency of, 58t
Desmethylvenlafaxine, 159t
Dexamethasone, 159t
Dextromethorphan
 CYP enzyme metabolism of, 158t, 159t
 drug interactions with, 152t
Diabetes mellitus, depression prevalence with, 162t
Diarrhea
 amitriptyline and, 70
 imipramine and, 68t
 serotonin uptake blockade and, 48t
 sertraline and, 70
 SSRIs and, 82t, 86t
Diazepam
 CYP enzyme metabolism of, 159t
 drug interactions with, 182-183
Diltiazem, 159t
Disopyramide, 159t
 drug interactions with, 152t
Dizziness
 amitriptyline and, 70
 imipramine and, 68t
 sertraline and, 70
 SSRIs and, 48t, 82t, 86t
Docetaxel, 159t
Dopamine uptake
 antidepressant potency and, 39t, 40
 drug selectivity and, 44t-45t
 SSRI metabolites and, 57, 58t, 60t
Drowsiness
 histamine receptor blockade and, 48t
 imipramine and, 68t
 SSRIs and, 82t, 86t, 87
Drug development. See also specific drug, eg, *Lithium*,
 development of.
 criteria for, 19t
 mechanism of action in, 18-19, 19t, 21
 molecular targeting in, 21
 signal-to-noise ratio in, 24
 site of action in, 18-20, 19
Drug interaction(s). See also specific drug, eg, *Monoamine*

242

oxidase inhibitor(s), *SSRI interaction with*.
 clearance rate and, 145-146
 CYP enzymes and, 143-144, 152t-153t
 pharmacodynamic, 144-145, 145t
 pharmacokinetic, 145, 145t-146t, 150
 CYP enzymes and, 155-157, 156, 160
 studies of, 173
Drug monitoring. See *Therapeutic drug monitoring*.
Drug potency
 concentration and, 43, 47, 50t, 51-52
 determination of, 33-35, 35
Dry mouth
 acetylcholine receptor blockade and, 48t
 amitriptyline and, 70
 imipramine and, 68, 68t
 sertraline and, 70
 SSRIs and, 82t, 86t
Dyspepsia, SSRIs and, 82t

Ejaculation, premature, SSRIs for, 91
Enantiomer. See also specific drug, eg, *Citalopram*
 enantiomer(s).
 definition of, 29-30
 drug monitoring and, 30
 pharmacokinetics of, 30
Encainide, 158t
Epilepsy, depression prevalence with, 162t
Erythromycin
 CYP enzyme metabolism of, 159t
 drug interactions with, 152t, 155
Estradiol, 159t
Ethosuximide, 159t
Ethylmorphine, 158t

Fatigue
 amitriptyline and, 70
 imipramine and, 68t
 sertraline and, 70
 SSRIs and, 82t, 86t, 87
Felodipine, 159t
Fenfluramine, 48t
Flecainide, 158t
Fluoxetine. See also *Norfluoxetine*.
 availability of, 18
 benzodiazepine interaction with, 66
 brand names of, by country, 234t-236t
 bupropion interaction with, 150

243

chirality of, 31
clearance of, age and gender and, 120t, 124-125
CYP enzymes and
 2C9/10 and, 193t
 2C19 and, 193t
 2D6 and, 179t-180t, 185, 186, 230t
 2D6 deficiency and, 163, 165t
 3A3/4 and, 193t
 inhibition by, 170t-171t
 metabolism of, 158t
development of, 16
dopamine uptake and, 39t
dosage of
 age and, plasma level and, 120t
 efficacy and, 85
 potency and, 50t, 51-52
drug interactions with, 152t, 181, 182-184, 188
effects of, on specific CYP enzymes, 176t-177t
efficacy of, acute, 92t, 93-95
half-life of, 60t, 109t, 118t, 119-123
 cirrhosis and, 127t
 metabolism of, 111t, 111-113
metabolites of, 116
 potency of, 57, 58t, 59
norepinephrine uptake and, 38t, 41
pharmacokinetics of, 109t
 linear *versus* nonlinear, 117-119
relapse rate with, 92t, 97-98
selectivity of, 41, 46t
serotonin uptake and, 37t, 41
 dosage and, 50t, 51-52
side effects of
 discontinuation rate from, 84
 incidence of, 82t-83t, 86t
 steady-state of, time to, 123
 structural formula of, 17
 in vitro profile of, 53
 washout of, 80, 123
Fluoxetine enantiomer(s), 45t
Fluvoxamine
 availability of, 18
 benzodiazepine interaction with, 66
 brand names of, by country, 234t-236t
 clearance of, age and gender and, 120t, 124-125
 CYP enzymes and
 1A2 and, 178
 2C9/10 and, 193t

244

 2C19 and, 193t
 2D6 and, 179t, 185, 230t
 2D6 deficiency and, 165t
 3A3/4 and, 193t
 inhibition by, 170t-171t
development of, 16
dopamine uptake and, 39t
dosage of
 age and, plasma level and, 120t
 potency and, 50t, 51-52
drug interactions with, 152t, 155, 178-179, 182-183, 190-192
effects of, on specific CYP enzymes, 176t-177t
efficacy of, acute, 92t, 93-94
half-life of, 60t, 109t, 118t, 123
 cirrhosis and, 127t
 metabolism of, 111t, 111-112
 norepinephrine uptake and, 38t, 41
 for obsessive-compulsive disorder, 18
 pharmacokinetics of, 109t
 linear *versus* nonlinear, 117-119
 relapse rate with, 92t, 98-99
 selectivity of, 41, 46t
 serotonin uptake and, 37t, 41
 dosage and, 50t, 51-52
 side effects of, incidence of, 82t-83t, 86t
 steady-state of, time to, 123
 structural formula of, 17
 in vitro profile of, 53
 washout of, 123
 withdrawal from, 122-123

Gender, SSRI clearance rate and, 120t-121t, 124-125
Guanabenz, adrenergic blocker interaction with, 49t
Guanethidine, antidepressant interaction with, 48t
Guillain-Barré syndrome, as SSRI side effect, 16

Haloperidol, 158t

Headache

 imipramine and, 68t
 SSRIs and, 48t, 82t, 86t

Heart

 acetylcholine receptor blockade and, 48t
 SSRIs and, 83t
 tricyclic antidepressant effects on, 55, 67, 74

Heart disease

 depression prevalence with, 162t

245

SSRI metabolism and, 125, 128
Hexobarbital, 158t
Histamine receptor blockade, 48t, 54
Hydroamphetamine, 158t
Hypertension drug(s), antidepressant interaction with, 48t-49t, 66-67
Hypotension, adrenergic blockade and, 49t

Imipramine
 CYP enzyme metabolism of, 158t, 159t
 dopamine uptake and, 39t
 norepinephrine uptake and, 38t, 41
 selectivity of, 41, 46t
 serotonin uptake and, 37t, 41
 side effects of, 68t, 69
Immunosuppressant drug(s), 159t
Inhibition constant, CYP enzyme effects and, 227-232
Insomnia
 amitriptyline and, 70
 imipramine and, 68t
 serotonin uptake blockade and, 48t
 sertraline and, 70
 SSRIs and, 82t

Jitteriness, norepinephrine uptake blockade and, 48t

Ketoconazole, drug interactions with, 153t, 155

Lidocaine, 158t-159t
Lithium
 development of, 20
 SSRI interaction with, 48t
Liver disease, SSRI metabolism and, 125-126, 127t
Loratadine, 159t
Lovastatin, 159t

Macrolide antibiotic(s), 159t
Mechanism of action. See also specific drug, eg, *Fluoxetine*,
 action mechanism of
 definition of, 18-19, 19t
Memory impairment, acetylcholine receptor blockade and,
 48t
Menstrual disorder, SSRIs and, 88t
Mephenytoin, 158t
Mephobarbital, 158t
Metoprolol, 158t

246

Mexiletine, 158t
Midazolam, 159t
Migraine, SSRIs and, 48t
Minodipine, 159t
Molecular targeting, in drug development, 21
Monoamine oxidase inhibitor(s)
 action mechanisms of, 16t, 22, 23
 development of, 20-21
 evolution of, 22
 SSRI interaction with, 48t, 79-80, 144-145
Muscarinic acetylcholine receptor blockade
 consequences of, 48t
 tricyclic antidepressants and, 67
Myocardial infarction, depression prevalence with, 162t

Nausea
 amitriptyline and, 70
 imipramine and, 68t
 serotonin uptake blockade and, 48t
 sertraline and, 70
 SSRIs and, 69, 82t, 86t
Nefazodone. See *Phenylpiperazine (Nefazodone)*.
Nervousness
 imipramine and, 68t
 SSRIs and, 82t, 86t, 87
Neuroleptic drug(s), drug interactions with, 184
Nicardipine, 159t
Nifedipine, 159t
Niludipine, 159t
Nisoldipine, 159t
Nitrendipine, 159t
Norepinephrine inhibitor(s), examples of, 16t
Norepinephrine uptake
 antidepressant potency and, 38t, 40, 41
 blockade of, consequences of, 48t
 drug selectivity and, 42, 44t-45t
 SSRI metabolites and, 57, 58t, 60t
Norfluoxetine
 biogenic amine uptake and, 45t
 chirality of, 31
 CYP 2D6 functions and, 180t
 CYP enzyme inhibition by, 59, 170t-171t
 drug interactions with, 155, 184, 188, 190-192
 half-life of, 60t, 119
 cirrhosis and, 127t
 pharmacokinetics of, 116
 potency of, 58t, 60t

247

steady-state of, time to, 123
washout of, 123
Nortriptyline
CYP enzyme metabolism of, 158t
norepinephrine uptake and, 41
selectivity ratio of, 41
serotonin uptake and, 41
Obsessive-compulsive disorder
fluvoxamine for, 18
SSRIs for, 91
Omeprazole, 159t
Opiate(s), 158t
Oral contraceptive(s), drug interactions with, 152t
Oxidative metabolism, 137, 139
Paclitaxel, 159t
Pain, chronic, depression prevalence with, 162t
Panic disorder, SSRIs for, 91
Paracetamol, 158t
Parkinson's disease
CYP enzyme 2D6 and, 138-140
depression prevalence with, 162t
Paroxetine
brand names of, by country, 234t-236t
clearance of, age and gender and, 121t, 124-125
CYP enzymes and
2C9/10 and, 193t
2C19 and, 193t
2D6 and, 179t, 185, 186-187, 228t
2D6 deficiency and, 163, 165t
3A3/4 and, 193t
inhibition by, 170t-171t
metabolism of, 158t
development of, 16
dopamine uptake and, 39t
dosage of
age and, plasma level and, 121t
efficacy and, 85
potency and, 50t, 51-52
drug interactions with, 152t-153t, 189, 190
effects of, on specific CYP enzymes, 176t-177t
efficacy of, acute, 92t, 93-95
half-life of, 60t, 109t, 118t, 119, 122
cirrhosis and, 127t
metabolism of, 111t, 113-114
metabolites of, 116

248

norepinephrine uptake and, 38t, 41
pharmacokinetics of, 109t
linear *versus* nonlinear, 117-119
renal disease and, 126, 127t
relapse rate with, 92t, 98-99
selectivity of, 41, 46t
serotonin uptake and, 37t, 41
dosage and, 50t, 51-52
side effects of
discontinuation rate from, 84
incidence of, 82t-83t, 86t
steady-state of, time to, 123
structural formula of, 17
in vitro profile of, 53
washout of, 123
withdrawal from, 122-123
Perhexiline, 158t
Perphenazine, 158t
Pharmacokinetics, linear *versus* nonlinear, 117-119
Phenformin, 158t
Phenobarbital, drug interactions with, 152t
Phenothiazine(s), development of, 20
Phenylpiperazine (Nefazodone)
action mechanism of, 16t, 25t
CYP enzyme metabolism of, 158t-159t
drug interactions with, 155
Phenytoin
CYP enzyme metabolism of, 158t
drug interactions with, 152t, 156, 181, 193t
Potency, determination of, 33-35, 35
Prazosin, 25t
Priapism, 49t
Progesterone, 159t
Propafenone, 158t-159t
Propranolol
CYP enzyme metabolism of, 158t
drug interactions with, 152t
Protein binding, concentration dependence of, 108
Quinidine
action mechanism of, 25t
CYP enzyme metabolism of, 159t
drug interactions with, 152t
Renal disease
depression prevalence with, 162t
SSRI metabolism and, 125-126, 127t, 128

249

Respiratory disturbance, SSRIs and, 83t, 86t

Rifampin, drug interactions with, 152t

Risperidone

antipsychotic efficacy of, dosage and, 146, 147

CYP enzyme metabolism of, 148, 158t

side effects of, 147, 148

Secobarbital, drug interactions with, 152t

Seizure

bupropion and, 149, 150

clozapine and, 148, 149

sodium channel blockade and, 49t

Selective serotonin reuptake inhibitor(s) (SSRIs). See *SSRI(s)*.

Serotonin uptake

antidepressant potency and, 37t, 40, 41

blockade of, consequences of, 48t

citalopram enantiomers and, 44t

dosage, plasma level, potency and, 50t

drug selectivity and, 42, 44t-45t

physiology of, 28-29

SSRI metabolites and, 57, 58t, 60t

Sertraline. See also *Desmethylsertraline*.

action mechanism of, 25t

brand names of, by country, 234t-236t

clearance of, age and gender and, 121t, 124-125

CYP enzymes and

2C9/10 and, 193t

2C19 and, 193t

2D6 and, 179t, 185, 187, 188-189, 230t

2D6 deficiency and, 165t

3A3/4 and, 193t

inhibition by, 170t-171t

metabolism of, 159t

development of, 16

dopamine uptake and, 39t

dosage of

age and, plasma level and, 121t

potency and, 50t, 51-52, 85

drug interactions with, 181, 182-183, 188-189, 190

effects of, on specific CYP enzymes, 176t-177t

efficacy of

acute, 92t, 93-96, 97

dosage and, 50t, 51-52

half-life of, 60t, 109t, 118t, 122

cirrhosis and, 127t

metabolism of, 111t, 114-115

metabolites of, 116-117

potency of, 57, 58t

norepinephrine uptake and, 38t, 41

pharmacokinetics of, 109t, 114-115

linear *versus* nonlinear, 117-119

relapse rate with, 92t, 98-99

selectivity of, 41, 46t

serotonin uptake and, 37t, 41

dosage and, 50t, 51-52

side effects of, 70

discontinuation rate from, 84

incidence of, 82t-83t, 86t

steady-state of, time to, 123

structural formula of, 17

in vitro profile of, 53

washout of, 123

Sexual dysfunction

amitriptyline and, 70

norepinephrine uptake blockade and, 48t

serotonin uptake blockade and, 48t

sertraline and, 70

SSRIs and, 86t, 87, 88t-89t

Signal-to-noise ratio

in drug development, 24

enantiomeric form and, 30

Site of action

concentration dependence of, 35

definition of, 18-20, 19

Sodium channel blockade

consequences of, 49t

by tricyclic antidepressants, 54

Somnolence

amitriptyline and, 70

sertraline and, 70

Sparteine, 158t

SSRI(s). See also specific drug, eg, *Fluoxetine*.

action mechanism of, 28

action sites of, 23-24, 52

advantages of, 28

brand names of, by country, 234t-236t

chirality of, 29-32

clearance of

age and gender and, 120t-121t, 124-125

organ impairment and, 125-126, 127t, 128-129

concentration-dependent effects of, 107-108, 108t

active metabolites and, 115-117

age and gender and, 120t-121t, 124-125

antidepressant efficacy as, 50t, 101-105, 103

half-life as, 109t, 118t, 122-123, 123
metabolism as, 110-115
organ impairment and, 125-126, 127t, 128-129
pharmacokinetics as, 117-119
plasma level as, 120t-121t
protein binding as, 108
cost of, 72-73
current popularity of, 13
CYP enzymes and, 98
 affinity for, 56
 inhibition by, 78
 metabolism of, 158t
development of, 16, 18, 23-24
discontinuation of, because of side effects, 84
dosage of
 age and, 120t-121t
 efficacy and, 85
 plasma level and potency and, 50t, 51-52
drug interactions with, 77-80
efficacy of, 69, 71t, 72
 acute, 91-98
 concentration dependence of, 50t, 101-105, 103
 on dopamine uptake, 39t, 40
 dose and, 85
 metabolites and, 60t
 on norepinephrine uptake, 38t, 40
 on serotonin uptake, 37t, 40
examples of, 15
half-lives of, 60t, 109t, 118t, 122-123, 123
 cirrhosis and, 126
for major depression, 75t
metabolism of, 110-115
metabolites of, 57, 59, 115-117
 action mechanisms of, 60t
 clinical relevance of, 61-62
 half-lives of, 60t
 potency of, 57, 58t, 60t
monoamine oxidase inhibitor interaction with, 48t, 79-80, 144-145
for obsessive-compulsive disorder, 91
overdose of, 77-78
for panic disorder, 91
pharmacokinetics of, linear *versus* nonlinear, 117-119
physician comfort level with, 63
plasma level of, dose and age and, 120t-121t
for premature ejaculation, 91
protein binding of, 108

safety of, 64-67, 65t, 77-80
selectivity of, 28-29, 46t
 biogenic amine uptake and, 42, 44t-46t, 48t-49t
 and effects on different neuroreceptors, 52, 53, 54-56
side effects of, 65t, 67-69, 70
 determination of, 80
 discontinuation rate from, 84
 dose dependence of, 81, 87, 88t, 98
 incidence of, 81, 82t-83t, 86t
 sexual, 87, 88t-89t
similarities in, 75-105
steady-state of, time to, 123
switching among, 98
therapeutic monitoring of, 73-74, 99-105
versus tricyclic antidepressants, differences in, 63-74
washout of, 80, 123
withdrawal from, 122-123
Steroid(s), 159t
Stroke, depression prevalence with, 162t
Sweating
 imipramine and, 68t
 SSRIs and, 83t, 86t
Sympathomimetic amine(s), antidepressant interaction with, 48t

Tachycardia
 acetylcholine receptor blockade and, 48t
 norepinephrine uptake blockade and, 48t
Tacrolimus, 159t
Tamoxifen, 159t
Terfenadine
 cardiac arrhythmias and, 155
 CYP enzyme metabolism of, 151, 155, 159t
 drug interactions with, 153t, 155, 190-191
Testosterone, 159t
Theophylline
 CYP enzyme metabolism of, 158t
 drug interactions with, 152t
Therapeutic drug monitoring
 to adjust dose upward, 101
 to avoid toxicity, 100-101
 decision making and, 104-105
 of enantiomer, 30
 fixed-dose studies as, 102
 lack of incentive for, 102
 of SSRIs, 73-74, 99-105
 of tricyclic antidepressants, 26, 73-74

Thioridazine, 158t
Timolol, 158t
Tolbutamide
 CYP enzyme metabolism of, 158t
 drug interactions with, 181, 193t
Trazodone, 158t
Tremor
 amitriptyline and, 70
 imipramine and, 68t
 norepinephrine uptake blockade and, 48t
 sertraline and, 70
 SSRIs and, 82t, 86t
Triacetyloleandomycin, 159t
Triazolam, 159t
Tricyclic antidepressant(s). See also specific drug, eg,
 Amitriptyline.
 action mechanisms of, 16t, 22, 23-25, 150-151
 alcohol interaction with, 65-66
 antihistamine effects of, 65
 antihypertensive drug interaction with, 48t-49t, 66-67
 cardiac effects of, 55, 67, 74
 clearance of, 24-25, 54-55, 151
 cost of, 72-73
 CYP enzyme metabolism of, 151, 158t
 demethylation of, 55
 potency and, 56
 development of, 20t, 20-21
 drug interactions with, 152t, 178-179, 184
 evolution of, 22
 for major depression, 72
 monitoring intake of, 26
 overdose of, 24, 65, 77
 CYP enzyme 2D6 deficiency and, 100-101
 symptoms of, 26, 151
 pharmacokinetics of, 151
 potency of, 69, 71t, 72
 dopamine uptake and, 39t, 40
 norepinephrine uptake and, 38t, 40
 serotonin uptake and, 37t
 response curves of, multiple concentrations and, 154
 safety of, 64-67, 65t
 selectivity of, 46t
 biogenic amine uptake and, 42, 44t-46t, 48t-49t
 side effects of, 25-26, 65t, 67-69, 68t, 70
 clearance rate and, 54-55
 sodium channel blockade by, 54
 versus SSRIs, 63-74

 therapeutic monitoring of, 73-74
Trimipramine, 158t
Tryptophan, SSRI interaction with, 48t
Tumor, terminal solid, depression prevalence with, 162t

Urinary frequency
 imipramine and, 68t
 SSRIs and, 83t, 86t
Urinary retention
 acetylcholine receptor blockade and, 48t
 imipramine and, 68t
 SSRIs and, 83t

Valproate, drug interactions with, 156

Venlafaxine
 action mechanism of, 16t
 CYP enzyme metabolism of, 158t

Verapamil, 159t

Visual disturbance
 acetylcholine receptor blockade and, 48t
 amitriptyline and, 70
 imipramine and, 68t
 sertraline and, 70
 SSRIs and, 82t

Vomiting, serotonin uptake blockade and, 48t

Warfarin
 CYP enzyme metabolism of, 158t, 180-181
 drug interactions with, 152t, 180-181
Weight gain, histamine receptor blockade and, 48t
Withdrawal syndrome, 122-123

Yohimbine, action mechanism of, 25t